These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12435701)

  • 1. env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors.
    Fikkert V; Cherepanov P; Van Laethem K; Hantson A; Van Remoortel B; Pannecouque C; De Clercq E; Debyser Z; Vandamme AM; Witvrouw M
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3954-62. PubMed ID: 12435701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in both env and gag genes are required for HIV-1 resistance to the polysulfonic dendrimer SPL2923, as corroborated by chimeric virus technology.
    Hantson A; Fikkert V; Van Remoortel B; Pannecouque C; Cherepanov P; Matthews B; Holan G; De Clercq E; Vandamme AM; Debyser Z; Witvrouw M
    Antivir Chem Chemother; 2005; 16(4):253-66. PubMed ID: 16130523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent and selective inhibition of HIV and SIV by prostratin interacting with viral entry.
    Witvrouw M; Pannecouque C; Fikkert V; Hantson A; Van Remoortel B; Hezareh M; De Clercq E; Brown SJ
    Antivir Chem Chemother; 2003 Nov; 14(6):321-8. PubMed ID: 14968938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication.
    de Vreese K; Kofler-Mongold V; Leutgeb C; Weber V; Vermeire K; Schacht S; Anné J; de Clercq E; Datema R; Werner G
    J Virol; 1996 Feb; 70(2):689-96. PubMed ID: 8551604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134.
    Kanbara K; Sato S; Tanuma J; Tamamura H; Gotoh K; Yoshimori M; Kanamoto T; Kitano M; Fujii N; Nakashima H
    AIDS Res Hum Retroviruses; 2001 May; 17(7):615-22. PubMed ID: 11375057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry.
    Marozsan AJ; Moore DM; Lobritz MA; Fraundorf E; Abraha A; Reeves JD; Arts EJ
    J Virol; 2005 Jun; 79(11):7121-34. PubMed ID: 15890952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
    Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP).
    Gonzalez E; Ballana E; Clotet B; Esté JA
    AIDS; 2011 Aug; 25(13):1557-83. PubMed ID: 21572303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region.
    Labrosse B; Treboute C; Alizon M
    J Virol; 2000 Mar; 74(5):2142-50. PubMed ID: 10666243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased HIV-1 sensitivity to neutralizing antibodies by mutations in the Env V3-coding region for resistance to CXCR4 antagonists.
    Hikichi Y; Yokoyama M; Takemura T; Fujino M; Kumakura S; Maeda Y; Yamamoto N; Sato H; Matano T; Murakami T
    J Gen Virol; 2016 Sep; 97(9):2427-2440. PubMed ID: 27368421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
    Keller PW; Morrison O; Vassell R; Weiss CD
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
    Ray N; Harrison JE; Blackburn LA; Martin JN; Deeks SG; Doms RW
    J Virol; 2007 Apr; 81(7):3240-50. PubMed ID: 17251281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second site escape of a T20-dependent HIV-1 variant by a single amino acid change in the CD4 binding region of the envelope glycoprotein.
    Baldwin CE; Berkhout B
    Retrovirology; 2006 Nov; 3():84. PubMed ID: 17134507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain.
    Deml L; Kratochwil G; Osterrieder N; Knüchel R; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):10-25. PubMed ID: 9300033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Polar Region of the HIV-1 Envelope Protein Determines Viral Fusion and Infectivity by Stabilizing the gp120-gp41 Association.
    Lu W; Chen S; Yu J; Behrens R; Wiggins J; Sherer N; Liu SL; Xiong Y; Xiang SH; Wu L
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein.
    Este JA; Schols D; De Vreese K; Van Laethem K; Vandamme AM; Desmyter J; De Clercq E
    Mol Pharmacol; 1997 Jul; 52(1):98-104. PubMed ID: 9224818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.
    Yuan C; Wang JY; Zhao HJ; Li Y; Li D; Ling H; Zhuang M
    Retrovirology; 2019 Dec; 16(1):36. PubMed ID: 31796053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.
    Witvrouw M; Fikkert V; Hantson A; Pannecouque C; O'keefe BR; McMahon J; Stamatatos L; de Clercq E; Bolmstedt A
    J Virol; 2005 Jun; 79(12):7777-84. PubMed ID: 15919930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.